{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:11:40Z","timestamp":1770977500650,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/cmr.0b013e32835c7e68","type":"journal-article","created":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T03:55:05Z","timestamp":1356148505000},"page":"47-54","source":"Crossref","is-referenced-by-count":42,"title":["Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Sebastian G.","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Moskalenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaily","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harleen K.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Sicular","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Harcharik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne M.","family":"Saenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002.","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R2-8-20210129","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R3-8-20210129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4 mediated inhibition in regulation of T-cell responses: mechanisms and manipulation in tumor immunotherapy.","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R5-8-20210129","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R6-8-20210129","first-page":"489","article-title":"Profile of ipilimumab and its role in the treatment of metastatic melanoma.","volume":"5","author":"Patel","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-8-20210129","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-8-20210129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jnci\/91.6.523","article-title":"Measuring response in solid tumors: unidimensional versus bidimensional measurement.","volume":"91","author":"James","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R10-8-20210129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CMR.0b013e328353e65c","article-title":"Ipilimumab in advanced melanoma: reports of long-lasting responses.","volume":"22","author":"Farolfi","year":"2012","journal-title":"Melanoma Res"},{"key":"R12-8-20210129","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CCO.0b013e328341edff","article-title":"Autoimmunity and treatment outcome in melanoma.","volume":"23","author":"Bouwhuis","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma.","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"R19-8-20210129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-010-0958-2","article-title":"Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).","volume":"60","author":"Di Giacomo","year":"2011","journal-title":"Cancer Immunol Immunother"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0b013e32835c7e68","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:24:12Z","timestamp":1621887852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201302000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e32835c7e68","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}